Sagittarius Bio

Executive Summary

Sagittarius Bio is a privately held, early-stage biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company is dedicated to developing innovative RNA and gene therapies aimed at treating immunological and inflammatory diseases, as well as cancer. Leveraging its proprietary platform, Sagittarius Bio seeks to address significant unmet medical needs by designing novel therapeutic modalities that modulate gene expression with high specificity and durability. While the company is still in preclinical stages and has not publicly disclosed its lead programs or pipeline, its focus on RNA-based approaches positions it within a rapidly evolving and validated therapeutic space. Given the company's recent founding and lack of disclosed funding or partnerships, it likely relies on seed or early venture capital support. The success of Sagittarius Bio will depend on its ability to generate compelling preclinical proof-of-concept data, attract further investment, and navigate the complex regulatory landscape for gene therapies. The therapeutic potential in immunology and oncology, combined with advances in RNA delivery technologies, provides a promising avenue for the company's future development.

Upcoming Catalysts (preview)

• Q3 2026Presentation of preclinical proof-of-concept data for lead program60% success
• Q4 2026Series A or B financing round announcement50% success
• Q1 2027Filing of an investigational new drug (IND) application30% success